Effects of morphine on pain-elicited and pain-suppressed behavior in CB1 knockout and wildtype mice

Psychopharmacology

Volumn 215, Issue 3, 2011, Pages 455-465

  Miller, Laurence L ^a   Picker, Mitchell J ^a   Schmidt, Karl T ^a   Dykstra, Linda A ^a  

^a University of North Carolina at Chapel Hill   (United States)

Author keywords

Antagonist; Antinociception; Cannabinoid; CB1; Knockout; Morphine; Opioid; Pain

Indexed keywords

ACETIC ACID; CANNABINOID 1 RECEPTOR; MORPHINE; RIMONABANT; NARCOTIC ANALGESIC AGENT; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; FEEDING BEHAVIOR; FEMALE; HOT PLATE TEST; KNOCKOUT MOUSE; LATENT PERIOD; LOCOMOTION; MALE; MOUSE; NONHUMAN; PAIN; PAIN THRESHOLD; PRIORITY JOURNAL; WILD TYPE; WRITHING TEST; ANIMAL; ANIMAL BEHAVIOR; C57BL MOUSE; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECT; GENETICS; MOUSE MUTANT; PAIN ASSESSMENT; PATHOPHYSIOLOGY;

ANALGESICS, OPIOID; ANIMALS; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MORPHINE; PAIN; PAIN MEASUREMENT; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1;

EID: 80052333893     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-011-2232-5     Document Type: Article

References (42)

1. Ates M, Hamza M, Seidel K, Kotalla CE, Ledent C, Guhring H (2003) Intrathecally applied flurbiprofren produces an endocannabinoiddependent antinociception in the rat formalin test. Eur J Neurosci 17: 597-604 (Pubitemid 36255896)
2. Booker L, Naidu PS, Razdan RK, Mahadevan A, Lichtman AH (2009) Evaluation of prevalent phytocannabinoids in the acetic acid model of visceral nociception. Drug Alcohol Depend 105: 42-47
3. Calignano A, La Rana G, Giuffrida A, Piomelli D (1998) Control of pain by endogenous cannabinoids. Nature 394: 277-281
4. Cichewicz DL, McCarthy (2003) Antinociceptive synergy between Δ9-tetrahydrocannabinol and opioids after oral administration. J Pharmacol Exp Ther 304: 1010-1015
5. Cota D, Marsican G, Tschop M, Grubler Y, Flachskamm C, Schubert M, Auer D et al (2003) The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipgenesis. J Clin Invest 112: 423-431 (Pubitemid 38063771)
6. Cox ML, Welch SP (2004) The antinociceptive effect of Delta-9- tetrahydrocannabinol in the arthritic rat. Eur J Pharmacol 493: 65-84
7. Cox ML, Haller VL, Welch SP (2007) Synergy between Δ9- tetrahydrocannabinol and morphine in the arthritic rat. Eur J Pharmacol 567: 125-130 (Pubitemid 46782831)
8. Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DK, Martin BR, Lichtman AH (2001) Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. PNAS 98: 9371-9376 (Pubitemid 32743923)
9. Diaz S, Farhang B, Hoien J, Stahlman M, Adatia N, Cox JM, Wagner EJ (2009) Sex differences in the cannabinoid modulation of appetite, body temperature and neurotransmission at POMC synapses. Neuroendocrinology 89: 424-440
10. Dubreucq S, Koehl M, Abrous DN, Mariscano G, Chaouloff F (2010) CB1 receptor deficiency decreases wheel-running activity: consequences on emotional behaviours and hippocampal neurogenesis. Exp Neurol. doi: 10.1016/j.expneurol. 2010.01.017
11. Haller VL, Stevens DL, Welch SP (2008) Modulation of opioids via protection of anandamide degradation by fatty acid amide hydrolase. Eur J Pharmacol 600: 50-58
12. Institute of Laboratory Animal Research, Division on Earth and Life Studies, National Research Council (2010) Guide for the care and use of laboratory animals. National Academy, Washington
13. Jarbe TU, DiPatrizio NV (2005) Delta9-THC induced hyperphagia and tolerance assessment: interactions between the CB1 receptor agonist delta9-THC and the CB1 receptor antagonist SR-141716 (rimonabant) in rats. Behav Pharmacol 16: 373-380 (Pubitemid 41404808)
14. Justinova Z, Munzar P, Panlilio LV, Yasar S, Redhi GH, Tanda G, Goldberg SR (2008) Blockade of THC-seeking behavior and relapse in monkeys by the cannabinoid CB(1)-receptor antagonist rimonabant. Neuropsychopharmacol 33: 2870-2877
15. Keeney BK, Raichlen DA, Meek TH, Wijeratne RS, Middleton KM, Gerdeman GL, Garland TJ (2008) Differential responses to a selective cannabinoid receptor antagonist (SR141716: rimonabant) in female mice from lines selectively bred for high voluntary wheel-running behavior. Behav Pharmacol 19: 812-820
16. Li D, Olszewski PK, Shi MK, Billington CJ, Kotz CM, Levine AS (2006) Effect of opioid receptor ligands injected into the rostral lateral hypothalamus on c-fos and feeding behavior. Brain Res 1096: 120-124 (Pubitemid 43928920)
17. Le Bars D, Gozariu M, Cadden SW (2001) Animal models of nociception. Pharmacol Rev 53: 597-692
18. Ledent C, Valverde O, Cossu G, Petetet F, Aubert JF, Beslot F et al (1999) Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 283: 401-404
19. Martin TJ, Zhang Y, Buechler N, Conklin DR, Eisenach JC (2005) Intrathecal morphine and ketorlac analgesia after surgery: comparison of spontaneous and elicited responses in rats. Pain 113: 376-385 (Pubitemid 40127521)
20. Mason DJ, Lowe J, Welch SP (1999) A diminution of delta9- tetrahydrocannabinol modulation of dynorphin A-(1-17) in conjunction with tolerance development. Eur J Pharmacol 381: 105-111 (Pubitemid 29518281)
21. Matson DJ, Broom DC, Carson SR, Baldassari J, Kehne J, Cortright DN (2007) Inflammation-induced reduction of spontaneous activity by adjuvant: a novel model to study the effect of analgesics in rats. J Pharmacol Exp Ther 320: 194-201 (Pubitemid 46025734)
22. Miller CC, Murray TF, Freeman KG, Edwards FG (2004) Cannabinoid agonst, CP 55940, facilitates intake of palatable foods when injected into the hindbrain. Physiol Behav 80: 611-616 (Pubitemid 38230958)
23. Mogil JS (2009) Animal models of pain: progress and challenges. Nat Rev Neurosci 10: 283-294
24. Naidu PS, Booker L, Cravatt BF, Lichtman AH (2009) Synergy between enzyme inhibitors of fatty acid amide hydrolase and cyclooxygenase in visceral nociception. J Pharmacol Exp Ther 329: 48-56
25. Negus SS, Rice KC (2009) Mechanisms of withdrawal-associated increases in heroin self-administration: pharmacological modulation of heroin vs food choice in heroin-dependent rhesus monkeys. Neuropsychopharmacol 34: 899-911
26. Negus SS, Morrissey EM, Rosenberg M, Cheng K, Rice KC (2010) Effects of kappa opioids in an assay of pain-depressed intracranial self-stimulation in rats. Psychopharmacology. doi: 10.1007/ s00213-009-1770-6
27. Pacheco DF, Klein A, Perez AC, Pacheco CMF, Francischi JN, Duarte ID (2008) The mu-opioid receptor agonist morphine, but not agonists at delta- or kappa-opioid receptors, induces peripheral antinociception mediated by cannabinoid receptors. Brit J Pharmacol 154: 1143-1149 (Pubitemid 351923053)
28. Pacheco DF, Klein A, Perez AC, Pacheco CMF, Francischi JN, Reis GML, Duarte IDG (2009) Central antinociception induced by μ- opioid receptor agonist morphine, but not Δ- or κ- is mediated by cannabinoid CB1 receptor. Brit J Pharmacol 158: 225-231
29. Pascual D, Goicoechea C, Suardiaz M, Martin MI (2005) A cannabinoid agonist, WIN 55, 212-2, reduces neuropathic nociception induced by paclitaxel in rats. Pain 118: 23-34 (Pubitemid 41566582)
30. Pereira Do Carmo G, Stevenson GW, Carlezon WA, Negus SS (2009) Effects of pain- and analgesia-related manipulations on intracranial self-stimulation in rats: further studies on pain-depressed behavior. Pain 144: 170-177
31. Pertwee RG (2006) The pharmacology of cannabinoid receptors and their ligands: an overview. Int J Obes 30: S13-S18
32. Richardson JD, Kilo S, Hargreaves KM (1998) Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain 75: 111-119 (Pubitemid 28254862)
33. Smith MA, Greene-Naples JL, Lyle MA, Iordanou JC, Felder JN (2009) The effects of repeated opioid administration on locomotor activity: I. Opposing actions of μ and κ receptors. J Pharmacol Exp Ther 330: 468-475
34. Stevenson GW, Bilsky EJ, Negus SS (2006) Targeting painsuppressed behaviors in preclinical assays of pain and analgesia: effects of morphine on acetic acid-suppressed feeding in C57Bl/ 6J mice. J Pain 7: 408-416 (Pubitemid 43794888)
35. Stevenson GW, Cormier J, Mercer H, Adams C, Dunbar C, Negus SS, Bilsky EJ (2009) Targeting pain-depressed behaviors in preclinical assays of pain and analgesia: drug effects on acetic acid-depressed locomotor activity in ICR mice. Life Sci 85: 309-315
36. Valverde O, Ledent C, Beslot F, Parmentier M, Roques BP (2000) Reduction of stress-induced analgesia but not of exogenous opioid effects in mice lacking CB1 receptors. Eur J Neurosci 12: 533-539 (Pubitemid 30142754)
37. Vigano D, Valenti M, Cascio MG, Di Marzo V, Parolaro D, Rubino T (2004) Changes in endocannabinoid levels in a rat model of behavioral sensitization. Eur J Neurosci 20: 1849-1857 (Pubitemid 39471578)
38. Viganò D, Rubino T, Vaccani A, Bianchessi S, Marmorato P, Castiglioni C, Parolaro D (2005) Molecular mechanisms involved in the asymmetric interaction between cannabinoid and opioid systems. Psychopharmacol Berl 182: 527-536 (Pubitemid 41464634)
39. Waldhoer M, Bartlett SE, Whistler JL (2004) Opioid receptors. Annu Rev Biochem 73: 953-990 (Pubitemid 39050391)
40. Wang Y, Guo J, Wang S, Fang Q, He F, Wang R (2009) Neuropeptide FF receptors antagonist, RF9, attenuates opioid-evoked hypothermia in mice. Peptides 29: 1183-1190
41. Ward SJ, Lefever TW, Rawls SM, Whiteside GT, Walker EA (2009) Age-dependent effects of the cannabinoid CB1 antagonist SR141716A on food intake, body weight change, and pruritus in rats. Psychopharmacology 206: 155-165
42. Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, Bonner TI (1999) Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci 96: 5780-5785 (Pubitemid 29234695)